|Application ||WB, E|
|Calculated MW||28741 Da|
|Antigen Region||220-250 aa|
|Other Names||Prostate-specific antigen, PSA, Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, Semenogelase, KLK3, APS|
|Target/Specificity||This HKLK3 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 220-250 amino acids from human HKLK3.|
|Format||Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HKLK3 Antibody (C234) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
Kim, S.T., et al. Prostate 70(16):1729-1738(2010)
Kuasne, H., et al. Cancer Invest. 28(9):917-924(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Sarrats, A., et al. OMICS 14(4):465-474(2010)
Gallagher, D.J., et al. Clin. Cancer Res. 16(10):2819-2832(2010)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.